Steven Ringel 6/15/26 Steven Ringel 6/15/26

When one vector isn’t enough: why dual-vector gene therapy matters

Read More

Steven Ringel 6/9/26 Steven Ringel 6/9/26

FDA's new prior knowledge guidance: why rare disease gene therapy no longer has to start from zero

Read More

Steven Ringel 6/3/26 Steven Ringel 6/3/26

KIZ-Mutation Retinitis Pigmentosa: A Textbook Case for Gene Replacement Therapy

Read More

Steven Ringel 6/1/26 Steven Ringel 6/1/26

Experimental Therapy Testing: How to know if a therapy is safe and effective before it reaches a patient

Read More

Steven Ringel 5/21/26 Steven Ringel 5/21/26

ASGCT 2026 Recap: How Personalized Gene Therapies Are Becoming Real for Rare Disease Families

Read More

Steven Ringel 5/5/26 Steven Ringel 5/5/26

How AI Can Cut the Cost of Personalized Gene Therapy

Read More

Steven Ringel 4/21/26 Steven Ringel 4/21/26

Who Owns the Cure? The Case for Patient Control in Rare Disease Drug Development

Read More

Steven Ringel 4/12/26 Steven Ringel 4/12/26

N-of-1 Therapy Explained: What are the steps and timelines?

Read More

Steven Ringel 4/12/26 Steven Ringel 4/12/26

The New York Times Wrote About Rare Disease Gene Therapy. Here Is What They Left Out

Read More

Steven Ringel 4/12/26 Steven Ringel 4/12/26

Patient-Derived Cells: The Essential Foundation for Personalized Drug Development.

Read More

Steven Ringel 4/12/26 Steven Ringel 4/12/26

Landscape Review: The State of Gene Therapy and ASO Development

Read More

Steven Ringel 4/12/26 Steven Ringel 4/12/26

Gene Replacement vs. Gene Editing: Are they the same thing?

Read More